Pre-ASCO China Webinar #2-Novel Oncology Therapeutics Dev in US and China

Join Zoom Meeting ; Webinar ID: 863 4356 2941

About this Event

Symposium will highlight the Early Oncology Drug Development in the US and China. A panel of key leaders of US and Chinese companies will showcase selected novel oncology NCE and cell therapy global and regional development.

Webinar Date:

China Time: Saturday May 16th, 9 AM

US EST Time: Friday, May 15th, 9 PM

US PST Time: Friday, May 15th, 6 PM

Conference Language: English

Venue: Live Zoom Webcast

Webinar Agenda


Dr. Michael Shi, USCACA; Global Program Clinical Head, Novartis


Prof. Li Zhang (Sun Yat-sen University Cancer Center) on behalf of China Phase I consortium

Rapid fire pipeline talk

Prof. Tim Yap (MD Anderson) on Early oncology Development

Dr. Sean Zhang, CEO, Hengrui Therapeutics

Dr. Jay Mei, Founder, Chairman & CEO of Antengene Corporation

Dr. Wen Luo, CEO, DeNovo Pharma

Dr. Yuntao Wan, President of Clinical development, CSPC


Speakers Bio


Dr. Michael Shi, USCACA; Global Program Clinical Head, Novartis

Dr. Michael Shi is the Global Program Clinical Head at Novartis Pharmaceuticals Corp. in East Hanover, New Jersey, USA. Dr. Shi provides key leadership role in the clinical development of multiple novel oncology/hematology products, including Tabrecta (capmatinib, INC280), Zykadia (ceritinib, LDK378), Adakveo (crizanlizumab, SEG101), Exjade/Jadenu, BGJ398, TKI258 (dovitinib) and PDR001. Most recently, he leads the development teams to achieve accelerated approval of TabrectaTM and ZykadiaTM in lung cancer indication and Adakveo TM in sickle cell disease, all under the US FDA breakthrough therapy designation. Dr. Shi also worked extensively in the areas of clinical development, translational medicine, and biomarker development at Merck & Co., Pfizer, Inc. and Sequenom, Inc. He also worked as the Program Director of Genetics Variation at NIH closely with Dr. Francis Collins on the International HapMap Project and an assistant professor at the University of Michigan Medical School. Dr. Shi received his medical education from Perking Union Medical College (Beijing, China), a Ph.D. in Molecular Pharmacology and Toxicology from the University of Southern California (Los Angeles, USA) and conducted a postdoctoral fellowship at Harvard Medical School (Boston, USA).


Prof. Li Zhang (Sun Yat-sen University Cancer Center)

Professor Li Zhang is Professor of Medical Oncology, Director of Medical Oncology Department and Phase I Unit of Sun Yat-Sen University Cancer Centre (SYSUCC), Deputy Director of Lung Cancer Research Centre of SYSU. He is also the member of ASCO, CSCO, ESMO, IASLC, MASCC and Board of Directors of MASCC (2015-2018), Member of communication committee of IASLC. He received his medical and master of clinical oncology degrees from SYSU and was board certified as a physician in medical oncology. He has completed training as a visiting fellow at the MD Anderson Cancer Centre, Houston; Fox Chase Cancer Centre, Philadelphia, USA and Institut Gustave Roussy, Paris, France.

Professor Zhang’s research interest is in the development of molecular, prognostic and therapeutic approaches to improve the care for patients with lung cancer and head and neck cancer. He is also actively involved in cancer palliative and supportive care like cancer pain management and chemotherapy induced nausea and vomiting (CINV). He contributes extensively to the Chinese Anti-Cancer Association (CACA) where he currently serves as Present-elect of the Committee of Rehabilitation and Palliative Care (CRPC), CACA. He is also a standing committee member of the Chinese Society of Clinical Oncology (CSCO) and President of immunotherapy expert committee of CSCO.

Professor Zhang has published more than 200 clinical papers in top-tier journals like: Lancet, Lancet Oncology, Journal of Clinical Oncology, Lancet Respiratory Medicine, JAMA Oncology, Annals of Oncology, JNCI, Support Care Cancer. He also presented abstracts to many major congresses like ASCO, WCLC, ESMO, MASCC meetings. He is an editorial board member of Clinical Lung Cancer, Cancer Communications, Chinese Journal of Clinical Oncology. At present, he is a senior consultant to the Centre of Drug Evaluation (CDE), Chinese Food and Drug Administration (CFDA) and had formerly drafted the CFDA Guidance for Industry: Clinical Trial for the Approval of Cancer Drugs and Biologics (second version, 2006).


Prof. Tim Yap (MD Anderson) on Early oncology Development

Dr. Timothy Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr. Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK.

Dr. Yap gained his BSc degree with First Class Honors in Immunology and Infectious Diseases at Imperial College London, UK, and was awarded the Huggett Memorial Prize. His BSc laboratory research involved an immunogenetics study into the human T-cell lymphotropic virus under the supervision of Professor Charles Bangham. He subsequently went on to attain his Medical degree from Imperial College London, UK, before completing general medical training in Oxford.


Dr. Sean Zhang, CEO, Hengrui Therapeutics

Sean Zhang, MD, FCP is the Chief Executive Officer (CEO) of Hengrui Therapeutics, Inc. (HTI) located in Princeton, NJ, USA. Dr. Zhang has extensive drug R&D experience from drug discovery through life cycle management. He has lead project teams to successfully conduct several clinical programs at different development stages at GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS), and Johnson and Johnson (JNJ). Dr. Zhang also devoted several years of his early career to drug discovery at Merck & Co. In addition to his 8 years medical practice in PLA General (301) hospital in Beijing China, Dr. Zhang also obtained his clinical fellowship training in Clinical Pharmacology at the National Institute of Health (NIH) Clinical Center, focusing on clinical pharmacology and drug development. In year 2012, Dr. Zhang was elected as Fellow of Clinical Pharmacology (FCP) for American College of Clinical Pharmacology. He has published more than 30 peer-reviewed papers and received numerous awards.


Dr. Jay Mei, Founder, Chairman & CEO of Antengene Corporation

Dr. Mei founded Antengene Corporation in Apr 2017. Antengene currently has 6 clinical stage and 6 pre-clinical discovery stage assets respectively in its pipeline. Since establishment, Antengene has completed two rounds of financing with Series A of USD 21 million (Aug. 2017) and Series B of USD 120 million (Jan. 2019). Currently, Antengene is conducting ten clinical trials in China and other APAC countries/regions, including two registration trials. The first commercial launch of Antengene’s lead pipeline product in China is expected in 2021. Antengene has entered into strategic partnership with Celgene (now BMS), AstraZeneca and Karyopharm Therapeutics over the past two years.

Prior to founding Antengene, Dr. Mei previously served as the Global Clinical Lead of Clinical Development at Celgene Corporation. Dr. Mei has over 25 years of experience in the clinical development of oncology therapeutics globally and successfully led the development of multiple oncology products, including REVLIMID® in China. REVLIMID® received NDA approval in China and launched in 2013. Outside of the China market, Dr. Mei was the clinical leader for the development of REVLIMID®, POMALYST®, IDHIFA®, etc., in more than 30 countries.

Before his role at Celgene, Dr. Mei served in multiple clinical development positions at Novartis Oncology as Global Clinical Program Head and at J&J Pharmaceutical Research & Development as early clinical development leader. Dr. Mei completed eight years of cancer and clinical research at the U.S. National Cancer Institute (NCI). Dr. Mei has also been the author of over 70 publications and holds multiple patents.


Dr. Wen Luo, CEO, DeNovo Pharma

Dr. Wen Luo is CEO and CSO of Denovo Biopharma, a leading precision medicine company developing innovative drugs in treating cancers and CNS diseases. Dr. Luo has 20 years of experience in biomedical research and industry including more than 10 years of experience in applying genomic technology in drug discovery and development.

Prior to founding Denovo Biopharma, Dr. Luo managed the genomic group and provided bioinformatic supports to a broad range of research projects across a number of therapeutic areas including oncology, hematology, inflammation and metabolic diseases at Ligand Pharmaceuticals. He was also responsible for developing clinical biomarkers for drugs in various stages of clinical trials. Before joining Ligand, he was senior bioinformatician at Incyte Genomic, where he managed one of the largest proteomic databases at the time, LifePro. He was also involved in discovering novel human genes and splice variants, and he was the co-inventor of patents covering 100s of novel genes derived from these findings. Prior to Incyte Genomics, he was a research scientist at Sugen (acquired by Pharmacia and then by Pfizer) working on drug target identification and validation for a number of novel kinases discovered at Sugen.

Dr. Luo was a Howard Hughes Medical Institute post-doc fellow at UCSF, and received his Ph.D. in molecular biology and biochemistry from Indiana University School of Medicine. Dr. Luo received Pre-Med training at Peking University and medical training at Peking Union Medical College.


Dr. Yuntao Wan, President of Clinical development, CSPC

Currently a Corporate Vice President and the President of Clinical Development at CSPC Pharmaceutical Group. Has over 20 years of experience in biopharmaceutical R&D. Held various positions at Mabspace (Transcenda), Bayer, Roche, Celgene, and Schering-Plough. Studied at Rutgers University in US and Fudan University in Shanghai.

Before joining CSPC, Yuntao was the Senior Vice President at Mabspace Suzhou in charge of oncology Clinical Development. Earlier experiences included as the China Head of Clinical Sciences at Bayer Beijing; as the Head of Clinical Operations at Roche Innovation Center Shanghai and as a Clinical Programs Leader at Roche Innovation Center New York. Yuntao also worked for a combined 15 years at Celgene and the legacy Schering-Plough Corp (now part of MSD) in New Jersey, USA.



US Chinese Anti-Cancer Association

U.S. Chinese Anti-Cancer Association (USCACA) is a non-profit professional organization founded in 2009. With members from academia, industry and government, USCACA facilitates collaboration among cancer research and physicians in the United States and China. Our current focus is on expediting novel cancer drug development by fostering clinical trial networks, sharing best practices and knowledge of clinical trial, and providing education and training opportunities. USCACA collaborates with Chinese Anti-Cancer Association, Chinese Society for Clinical Oncology, and other professional associations. Our mandate is to improve cancer treatment through research, education, and collaboration.


eChinaHealth is an integrated media for China healthcare and pharmaceutical segments. eChinaHealth services include digital platform and media, conferences and events, data and consulting, and social network and community.

eChinaHealth is exclusive China sale representation for ASCO Publications including “Journal of Clinical Oncology”, “Journal of Clinical Practice”, and “ASCO Post”, etc. eChinaHealth and ASCO plan to organize a series of ASCO Direct™ conference in China. The ASCO Direct™ program is an educational initiative that condenses highlights from ASCO Meeting into a 1-day China program, in an effort to provide Chinese doctors’ access to the most cutting-edge research discussed at ASCO meetings.




BeiGene is a biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Our mission is to become a global leader in the discovery, development, and commercialization of innovative, molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.


Welcome to john the ASCO China Conference WeChat Groups! You can follow up the latest on ASCO China conferences and network with fellow Chinese and global attendees. We will post the conference information including the links on recorded conference videos. Please use your WeChat to scan the QR code to join.